{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:22:18Z","timestamp":1788686538818,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,5]]},"DOI":"10.7759\/cureus.55563","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:12:51Z","timestamp":1709647971000},"source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor\/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway"],"prefix":"10.7759","author":[{"given":"Randy","family":"Felber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"New","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne I","family":"Riskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7106a4","article-title":"Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants - United States, June 2021-January 2022","volume":"71","author":"Lambrou AS","year":"2022","unstructured":"Lambrou AS, Shirk P, Steele MK, et al.. Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants - United States, June 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:206-11. 10.15585\/mmwr.mm7106a4","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072048","article-title":"Angiotensin II type I receptor (AT1R): the gate towards COVID-19-associated diseases","volume":"27","author":"El-Arif G","year":"2022","unstructured":"El-Arif G, Khazaal S, Farhat A, et al.. Angiotensin II type I receptor (AT1R): the gate towards COVID-19-associated diseases. Molecules. 2022, 27:2048. 10.3390\/molecules27072048","journal-title":"Molecules"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13202","article-title":"ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19","volume":"289","author":"Tetlow S","year":"2021","unstructured":"Tetlow S, Segiet-Swiecicka A, O'Sullivan R, et al.. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J Intern Med. 2021, 289:688-99. 10.1111\/joim.13202","journal-title":"J Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2022.108286","article-title":"Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2","volume":"117","author":"Golcuk M","year":"2022","unstructured":"Golcuk M, Yildiz A, Gur M. Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2. J Mol Graph Model. 2022, 117:108286. 10.1016\/j.jmgm.2022.108286","journal-title":"J Mol Graph Model"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2020.1814143","article-title":"COVID-19 and renin-angiotensin system modulators: what do we know so far?","volume":"18","author":"de la Cruz A","year":"2020","unstructured":"de la Cruz A, Ashraf S, Vittorio TJ, Bella JN. COVID-19 and renin-angiotensin system modulators: what do we know so far?. Expert Rev Cardiovasc Ther. 2020, 18:743-8. 10.1080\/14779072.2020.1814143","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13124","article-title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19: a meta-analysis and systematic review","volume":"13","author":"Hassib M","year":"2021","unstructured":"Hassib M, Hamilton S, Elkhouly A, Li Y, Kaplan AC. Renin-angiotensin-aldosterone system inhibitors and COVID-19: a meta-analysis and systematic review. Cureus. 2021, 13:e13124. 10.7759\/cureus.13124","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14101","article-title":"Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study","volume":"23","author":"Bauer AZ","year":"2021","unstructured":"Bauer AZ, Gore R, Sama SR, et al.. Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study. J Clin Hypertens (Greenwich). 2021, 23:21-7. 10.1111\/jch.14101","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchy.2021.100088","article-title":"COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system","volume":"9","author":"An J","year":"2021","unstructured":"An J, Zhou H, Wei R, et al.. COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system. Int J Cardiol Hypertens. 2021, 9:100088. 10.1016\/j.ijchy.2021.100088","journal-title":"Int J Cardiol Hypertens"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa447","article-title":"Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome","volume":"222","author":"Lam KW","year":"2020","unstructured":"Lam KW, Chow KW, Vo J, et al.. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020, 222:1256-64. 10.1093\/infdis\/jiaa447","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.04.001","article-title":"Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: insights from the BRACE CORONA trial","volume":"249","author":"Macedo AV","year":"2022","unstructured":"Macedo AV, de Barros E Silva PG, de Paula TC, et al.. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: insights from the BRACE CORONA trial. Am Heart J. 2022, 249:86-97. 10.1016\/j.ahj.2022.04.001","journal-title":"Am Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050051","article-title":"Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study","volume":"11","author":"Wallace AW","year":"2021","unstructured":"Wallace AW, Cirillo PM, Ryan JC, Krigbaum NY, Badathala A, Cohn BA. Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study. BMJ Open. 2021, 11:e050051. 10.1136\/bmjopen-2021-050051","journal-title":"BMJ Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13119","article-title":"Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States","volume":"288","author":"Imam Z","year":"2020","unstructured":"Imam Z, Odish F, Gill I, et al.. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020, 288:469-76. 10.1111\/joim.13119","journal-title":"J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23836","article-title":"Safety of ACEi and ARB in COVID-19 management: a retrospective analysis","volume":"45","author":"Kumar S","year":"2022","unstructured":"Kumar S, Nikravesh M, Chukwuemeka U, et al.. Safety of ACEi and ARB in COVID-19 management: a retrospective analysis. Clin Cardiol. 2022, 45:759-66. 10.1002\/clc.23836","journal-title":"Clin Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002584","article-title":"Baseline use of angiotensin-converting enzyme inhibitor\/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients","volume":"38","author":"Shah P","year":"2020","unstructured":"Shah P, Owens J, Franklin J, Jani Y, Kumar A, Doshi R. Baseline use of angiotensin-converting enzyme inhibitor\/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients. J Hypertens. 2020, 38:2537-41. 10.1097\/HJH.0000000000002584","journal-title":"J Hypertens"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2020.1826308","article-title":"Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"18","author":"Lo KB","year":"2020","unstructured":"Lo KB, Bhargav R, Salacup G, Pelayo J, Albano J, McCullough PA, Rangaswami J. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2020, 18:919-30. 10.1080\/14779072.2020.1826308","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01639-2","article-title":"Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use associated with reduced mortality and other disease outcomes in US veterans with COVID-19","volume":"82","author":"Rizk JG","year":"2022","unstructured":"Rizk JG, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E, Ahluwalia A. Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use associated with reduced mortality and other disease outcomes in US veterans with COVID-19. Drugs. 2022, 82:43-54. 10.1007\/s40265-021-01639-2","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-021-00462-w","article-title":"Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population","volume":"28","author":"Sattar Y","year":"2021","unstructured":"Sattar Y, Mukuntharaj P, Zghouzi M, et al.. Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population. High Blood Press Cardiovasc Prev. 2021, 28:405-16. 10.1007\/s40292-021-00462-w","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2020.489","article-title":"Safety of ACE-I and ARB medications in COVID-19: a retrospective cohort study of inpatients and outpatients in California","volume":"5","author":"Rubin SJ","year":"2021","unstructured":"Rubin SJ, Falkson SR, Degner NR, Blish CA. Safety of ACE-I and ARB medications in COVID-19: a retrospective cohort study of inpatients and outpatients in California. J Clin Transl Sci. 2021, 5:e8. 10.1017\/cts.2020.489","journal-title":"J Clin Transl Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000515232","article-title":"Outcomes of hospitalized COVID-19 patients receiving renin-angiotensin system blockers and calcium channel blockers","volume":"52","author":"Choksi TT","year":"2021","unstructured":"Choksi TT, Zhang H, Chen T, Malhotra N. Outcomes of hospitalized COVID-19 patients receiving renin-angiotensin system blockers and calcium channel blockers. Am J Nephrol. 2021, 52:250-60. 10.1159\/000515232","journal-title":"Am J Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26588","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: meta-analysis","volume":"93","author":"Yokoyama Y","year":"2021","unstructured":"Yokoyama Y, Aikawa T, Takagi H, Briasoulis A, Kuno T. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: meta-analysis. J Med Virol. 2021, 93:2084-9. 10.1002\/jmv.26588","journal-title":"J Med Virol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13429","article-title":"Renin-angiotensin-aldosterone system blockers prior to hospitalization and their association with clinical outcomes in coronavirus disease 2019 (COVID-19)","volume":"13","author":"Banwait R","year":"2021","unstructured":"Banwait R, Singh D, Blanco A, Rastogi V, Abusaada K. Renin-angiotensin-aldosterone system blockers prior to hospitalization and their association with clinical outcomes in coronavirus disease 2019 (COVID-19). Cureus. 2021, 13:e13429. 10.7759\/cureus.13429","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2015","article-title":"Association between baseline use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19","volume":"62","author":"Thomas SA","year":"2022","unstructured":"Thomas SA, Puskarich M, Pulia MS, et al.. Association between baseline use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19. J Clin Pharmacol. 2022, 62:777-82. 10.1002\/jcph.2015","journal-title":"J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151418","article-title":"In-hospital use of ACE inhibitors\/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients","volume":"131","author":"Li S","year":"2021","unstructured":"Li S, Sarangarajan R, Jun T, et al.. In-hospital use of ACE inhibitors\/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021, 131:e151418. 10.1172\/JCI151418","journal-title":"J Clin Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-020-01291-4","article-title":"Outcomes in patients with covid-19 infection taking ACEI\/ARB","volume":"22","author":"Rico-Mesa JS","year":"2020","unstructured":"Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with covid-19 infection taking ACEI\/ARB. Curr Cardiol Rep. 2020, 22:31. 10.1007\/s11886-020-01291-4","journal-title":"Curr Cardiol Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060305","article-title":"Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study","volume":"12","author":"Jeffery MM","year":"2022","unstructured":"Jeffery MM, Oliveira J E Silva L, Bellolio F, Garovic VD, Dempsey TM, Limper A, Cummins NW. Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study. BMJ Open. 2022, 12:e060305. 10.1136\/bmjopen-2021-060305","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa064","article-title":"A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers","volume":"7","author":"Grover A","year":"2021","unstructured":"Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2021, 7:148-57. 10.1093\/ehjcvp\/pvaa064","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12665","article-title":"Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment","volume":"18","author":"Wang Y","year":"2022","unstructured":"Wang Y, Li M, Kazis LE, Xia W. Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment. Alzheimers Dement. 2022, 18:911-23. 10.1002\/alz.12665","journal-title":"Alzheimers Dement"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2021.08.018","article-title":"Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells","volume":"16","author":"Iwanski J","year":"2021","unstructured":"Iwanski J, Kazmouz SG, Li S, et al.. Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. Stem Cell Reports. 2021, 16:2459-72. 10.1016\/j.stemcr.2021.08.018","journal-title":"Stem Cell Reports"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2177","article-title":"RAAS blockade and COVID-19: mechanistic modeling of MAS and AT1 receptor occupancy as indicators of pro-inflammatory and anti-inflammatory balance","volume":"109","author":"Melissa Hallow K","year":"2021","unstructured":"Melissa Hallow K, Dave I. RAAS blockade and COVID-19: mechanistic modeling of MAS and AT1 receptor occupancy as indicators of pro-inflammatory and anti-inflammatory balance. Clin Pharmacol Ther. 2021, 109:1092-103. 10.1002\/cpt.2177","journal-title":"Clin Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.958418","article-title":"Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period","volume":"13","author":"Sonaglioni A","year":"2022","unstructured":"Sonaglioni A, Lombardo M, Albini A, et al.. Charlson comorbidity index, neutrophil-to-lymphocyte ratio and undertreatment with renin-angiotensin-aldosterone system inhibitors predict in-hospital mortality of hospitalized COVID-19 patients during the omicron dominant period. Front Immunol. 2022, 13:958418. 10.3389\/fimmu.2022.958418","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205587-sars-cov-2-and-the-angiotensin-converting-enzyme-2-receptor-angiotensin-converting-enzyme-inhibitorangiotensin-2-receptor-blocker-utilization-and-a-shift-towards-the-renin-angiotensin-aldosterone-system-classical-pathway","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:12:55Z","timestamp":1709647975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205587-sars-cov-2-and-the-angiotensin-converting-enzyme-2-receptor-angiotensin-converting-enzyme-inhibitorangiotensin-2-receptor-blocker-utilization-and-a-shift-towards-the-renin-angiotensin-aldosterone-system-classical-pathway"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.55563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}